FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma

Share:

Listens: 0

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

Science

FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma FDA medical oncologists discuss the January 14, 2019, approval of cabozantinib for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.